secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001213900-25-120360
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox
--------------------------------------------------------------------------------

- Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.
- VLX-1005 is a first-in-class, potent 12-LOX inhibitor with FDA Orphan Drug and Fast Track designations for HIT.
- Phase 2 interim results demonstrated encouraging reductions in thromboembolic events; no deaths or serious AEs in Phase 1.
- HIT affects ~56,000 confirmed diagnoses annually in the U.S.; current therapies do not address immune-driven pathogenesis.
- Deal adds VLX-1005 to Cadrenal's anticoagulation pipeline alongside tecarfarin and frunexian, targeting $3B+ peak revenue potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025120360/0001213900-25-120360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025120360/ea0269180-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-120360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer